Go back

Experts divided over risk of pharma research exodus

Regulations decried by industry weighed against importance of EU biomedical talent

Experts are divided on whether pharmaceutical companies will cut research and innovation investment in the EU and US over regulatory concerns. 

Pharma giants warn that investment could shift due to new laws such as an EU plan to link regulatory protections for new treatments to the speed of their rollout. But Elizabeth Kuiper, an associate director at the European Policy Centre think tank, believes investment flight will be stemmed by the need for talented researchers.

This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Pivot-RP users can log in and view the article via this link.